17
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T40305 | BRD4-IN-2 | BRD4-IN-2 | |
BRD4-IN-2 is a bromodomain BRD4 inhibitor with an IC 50 value of 9.9 nM. | |||
T64117 | BRD4-BD1-IN-2 | Epigenetic Reader Domain | |
BRD4-BD1-IN-2 is a selective and potent BRD4-BD1 inhibitor with an IC50 value of 2.51 µM, which is 20-fold greater than the inhibitory activity against BRD4-BD2.BRD4-BD1-IN-2 can be used in the study of cardiovascular an... | |||
T62540 | PARP1/BRD4-IN-2 | ||
PARP1/BRD4-IN-2 is a potent and selective inhibitor of PARP1 (IC50: 197 nM) and BRD4 (IC50: 238 nM).PARP1/BRD4-IN-2 inhibits DNA damage repair, blocks the G0/G1 cell cycle transition, and induces apoptosis.PARP1/BRD4-IN-... | |||
T64192 | BRD4 D1-IN-2 | ||
BRD4 D1-IN-2 (compound 26) is a selective and potent inhibitor of BRD4 D1 with an IC50 value of less than 0.092 μM. BRD4 D1-IN-2 has a 15 nM affinity for BRD4 D1 and is more than 500-fold selective for BRD2 D1 and BRD4 D... | |||
T63707 | BRD4-BD1/2-IN-2 | ||
BRD4-BD1/2-IN-2 is a potent inhibitor of BRD4-BD2, capable of acting on both BRD4 BD2 (IC50<0.5 nM) and BRD4 BD1 (IC50<300 nM). | |||
T61791 | BRD4-BD1/2-IN-1 | ||
BRD4-BD1/2-IN-1 is a highly effective inhibitor of BRD4, specifically targeting the BRD4 BD-1 and BRD4 BD-2 domains with IC 50 values of <100 nM each (US20150148375A1, compound 5) [1]. | |||
T3504 | AZD5153 6-Hydroxy-2-naphthoic acid | AZD5153,AZD-5153 HNT salt | Epigenetic Reader Domain |
AZD5153 6-Hydroxy-2-naphthoic acid (AZD5153) is a potent triazolopyridazine-based Bromodomain (BRD4) and Extraterminal (BET) inhibitor used in cancer treatments. | |||
T19618 | (R)-(-)-JQ1 Enantiomer | Epigenetic Reader Domain | |
(R)-(-)-JQ1 Enantiomer is the stereoisomer of (+)-JQ1. (+)-JQ1 is a BET bromodomain inhibitor, acting on BRD4(1/2)(IC50 of 77 nM/33 nM in a cell-free assay) | |||
T10773 | CF53 | Epigenetic Reader Domain , CDK | |
CF53 is a highly potent, selective and orally active inhibitor of BET protein, with a Ki of <1 nM, Kd of 2.2 nM and an IC50 of 2 nM for BRD4 BD1. CF53 binds to both the BD1 and BD2 domains of BRD2, BRD3, BRD4, and BRDT B... | |||
T10520 | BET-IN-2 | Epigenetic Reader Domain | |
BET-IN-2 is a BET inhibitor (IC50: 52 nM for BRD4-BD1). | |||
T63991 | BRD4/CK2-IN-1 | ||
BRD4/CK2-IN-1 is the first potent, orally active dual-target inhibitor of BRD4/CK2 (bromodomain-containing protein 4/casein kinase 2), acting on both BRD4 (IC50: 180 nM) and CK2 (IC50: 230 nM). In triple-negative breast ... | |||
T61327 | BRD4 Inhibitor-15 | ||
BRD4 Inhibitor-15 (compound 13) is a highly potent and specific inhibitor of BRD4, effectively inhibiting it with an IC50 of 18 nM. By regulating the Bcl-2/Bax proteins and activating the caspase-3 signaling pathway, BRD... | |||
T78956 | PROTAC BRD3/BRD4-L degrader-2 | Epigenetic Reader Domain | |
PROTAC BRD3/BRD4-L degrader-2, a PROTAC molecule, selectively degrades cellular BRD3 and BRD4-L with K i values of 16.91 and 2.8 nM, respectively, and exhibits robust antitumor activity in mouse xenograft models, serving... | |||
T36628 | PROTAC BRD4 Degrader-8 | PROTAC BRD4 Degrader-8 | PROTACs |
PROTAC BRD4 Degrader-8 is a potent BRD4 inhibitor, with IC50s of 1.1 nM and 1.4 nM for BRD4 BD1 and BD2, respectively. PROTAC BRD4 Degrader-8 is capable of potently degrading the BRD4 protein in PC3 prostate cancer cells... | |||
T18067 | Lenalidomide-PEG1-azide | Others | |
Lenalidomide-PEG1-azide is an E3 ligase ligand-linker conjugate that incorporates the cereblon ligand based on Lenalidomide and a linker. It is designed for use in the development of PROTAC BRD4 Degrader-2[1]. | |||
T36103 | TW9 | TW9 | |
TW9 is a dual inhibitor of bromodomain 2 (BD2) in bromodomain-containing protein 4 (BRD4) and histone deacetylase 1 (HDAC1; IC50s = 0.074 and 0.29 μM, respectively).1It is selective for BD2 over BD1 in BRD4 (IC50= 0.72 μ... | |||
T38381 | CAY17c | ||
CAY17c is an inhibitor of bromodomain-containing protein 4 (BRD4; IC50= 0.71 μM), as well as class I histone deacetylases (HDACs; IC50s = 0.046, 0.058, 0.075, and 0.167 μM for HDAC1, -2, -3, and -8, respectively) and cla... |